Intensive glucose control in patients with type 2 diabetes - 15-year follow-up.

Reaven, Peter D., Emanuele, Nicholas V., Wiitala, Wyndy L., Bahn, Gideon D., Reda, Domenic J., McCarren, Madeline, Duckworth, William C., Hayward, Rodney A.·2019·New England Journal of Medicine
DOI 10.1056/nejmoa1806802

Cited by (226)

Items 101–200 of 226

  1. Markers of cholesterol synthesis are elevated in adolescents and young adults with type 2 diabetes
    Ivana Semova, Amy E. Levenson, Joanna Krawczyk, Kevin H. Bullock, Kathryn Williams, Raj Paul Wadwa, Philip R. Khoury, Thomas R. Kimball, Elaine M. Urbina, Sarah D. de Ferranti et al. · 2020 · Pediatric Diabetes
  2. Predictors of blood glucose change and microvascular complications of type 2 diabetes mellitus patients in Felege Hiwot and Debre Markos referral hospital, North West Ethiopia
    Nigusie Gashaye Shita, Ashagrie Sharew Isayu · 2022 · BMC Endocrine Disorders
  3. Intensive Glucose Control and Type 2 Diabetes — 15 Years On
    Peter D. Reaven, Rodney A. Hayward, Jin J. Zhou · 2019 · New England Journal of Medicine
  4. Legacy in Cardiovascular Risk Factors Control: From Theory to Future Therapeutic Strategies?
    Lucie Pothen, Jean‐Luc Balligand · 2021 · Antioxidants
  5. Effect of a multicomponent quality improvement strategy on sustained achievement of diabetes care goals and macrovascular and microvascular complications in South Asia at 6.5 years follow-up: Post hoc analyses of the CARRS randomized clinical trial
    Ali, Mohammed K., Singh, Kavita, Kondal, Dimple, Devarajan, Raji, Patel, Shivani A., Menon, V. Usha, Varthakavi, Premlata K., Vishwanathan, Vijay, Dharmalingam, Mala, Bantwal, Ganapati et al. · 2024 · PLOS Medicine
  6. Comparative Effectiveness of Glucose-Lowering Drugs for Type 2 Diabetes
    Apostolos Tsapas, Thomas Karagiannis, Ioannis Avgerinos, David Richard Matthews, Eleni Bekiari · 2021 · Annals of Internal Medicine
  7. Long-term effects of lowering postprandial glucose level on cardiovascular outcomes in early-stage diabetic patients with coronary artery disease: 10-year post-trial follow-up analysis of the DIANA study
    Yu Kataoka, Satoshi Yasuda, Yasuhide Asaumi, Satoshi Honda, Teruo Noguchi, Yoshihiro Miyamoto, Kazuhiro Sase, Noriaki Iwahashi, Takayuki Kawamura, Masami Kosuge et al. · 2023 · Journal of Diabetes and its Complications
  8. Prevención de ictus en pacientes con diabetes mellitus tipo 2 o prediabetes. Recomendaciones del Grupo de Estudio de Enfermedades Cerebrovasculares de la Sociedad Española de Neurología
    Fuentes, B., Amaro, S., Alonso de Leciñana, M., Arenillas, J.F., Ayo-Martín, O., Castellanos, M., Freijo, M., García-Pastor, A., Gomis, M., Gómez Choco, M. et al. · 2021 · Neurología
  9. Types of Nursing Intervention on Improving Quality of Life among Patients with Diabetes Mellitus: A Systematic Review
    Agung Samsu Alam, Amin Samiasih, Mohammad Fatkhul Mubin, Satriya Pranata, Reina Dhamanik · 2023 · Current Diabetes Reviews
  10. Recent applications and advancement of conductive hydrogels in biosensing, bioelectronics and bioengineering
    Shiyu Chen, Tao Feng, Zeng‐Qiang Wu, Ning Bao · 2025 · Microchimica Acta
  11. Recent advances in the pharmacotherapeutic management of diabetic kidney disease
    Tomasz J. Block, Duygu Batu, Mark Emmanuel Cooper · 2022 · Expert Opinion on Pharmacotherapy
  12. Impact of Diabetes and Glycemia on Cardiac Improvement and Adverse Events Following Mechanical Circulatory Support
    Christos P. Kyriakopoulos, Iosif Taleb, Eleni Tseliou, Konstantinos Sideris, Rana Hamouche, Eleni Maneta, Marisca Nelson, Ethan Krauspe, Sean Selko, Joseph R. Visker et al. · 2024 · Journal of the American Heart Association
  13. Prevalence of cardiovascular disease risk factors in Chinese patients with type 2 diabetes mellitus, 2013–2018
    Chenchen Wang, Zuoling Xie, Xi Huang, Zheng Wang, Haiyan Shangguan, Shaohua Wang · 2022 · Current Medical Research and Opinion
  14. Analysis of the effect of liraglutide on glycemic variability in patients with type 2 diabetes
    Yuling Xing, Jinhu Chen, Liying Zhao, Huijuan Ma · 2020 · Endocrine Journal
  15. Novel cardiovascular metabolic risk factor mechanisms and therapeutic opportunities
    Paul Charles Evans, Gemma Vilahur, Petra Kleinbongard, Elena Osto, Carol Ann Remme, Rosalinda Madonna, Dunja Aksentijević, Harald Sourij, Sean M. Davidson, Donato Santovito et al. · 2026 · European Heart Journal
  16. Remodeling of the Intracardiac Ganglia During the Development of Cardiovascular Autonomic Dysfunction in Type 2 Diabetes: Molecular Mechanisms and Therapeutics
    Anthony J. Evans, Yulong Li · 2024 · International Journal of Molecular Sciences
  17. Reduced Cell Excitability of Cardiac Postganglionic Parasympathetic Neurons Correlates With Myocardial Infarction-Induced Fatal Ventricular Arrhythmias in Type 2 Diabetes Mellitus
    Wenfeng Hu, Dongze Zhang, Huiyin Tu, Yu-Long Li · 2021 · Frontiers in Neuroscience
  18. Cardiovascular events after a dramatic reduction of HbA1c in hospitalized subjects with type 2 diabetes and high long-term glucose exposure
    Vincent Rigalleau, Alice Larroumet, Claire Ducos, Marine Rigo, Marie‐Amélie Barbet‐Massin, Camille Majchrzak, Kamel Mohammedi, Laurence Baillet‐Blanco, Marie Monlun, Lila Rami Arab et al. · 2022 · Journal of Diabetes and its Complications
  19. Strategies to alter the trajectory of atherosclerotic cardiovascular disease
    Chris J. Packard · 2019 · Current Opinion in Lipidology
  20. Lack of Glycemic Legacy Effects in the Veterans Affairs Diabetes Trial
    Kasia J. Lipska, Neda Laiteerapong · 2019 · New England Journal of Medicine
  21. Hydrogen Peroxide Scavenging Restores N-Type Calcium Channels in Cardiac Vagal Postganglionic Neurons and Mitigates Myocardial Infarction-Evoked Ventricular Arrhythmias in Type 2 Diabetes Mellitus
    Dongze Zhang, Huiyin Tu, Wenfeng Hu, Bin Duan, Matthew Christopher Zimmerman, Yu‐Long Li · 2022 · Frontiers in Cardiovascular Medicine
  22. Optimal fasting glucose levels with regard to cardiovascular and mortality outcomes in people treated with or without antidiabetic medication
    Hae Hyuk Jung, Sunhwa Lee · 2019 · Diabetes Obesity and Metabolism
  23. Beyond Blood Glucose and Blood Pressure Control in Type 2 Diabetes: Alternative Management Strategies to Prevent the Development and Progression of CKD
    Wendy L. Wright, Scott Urquhart, Stephen Brunton · 2023 · Journal of Primary Care & Community Health
  24. Long-term follow-up of intensive glycaemic control in type 2 diabetes
    Kershaw V. Patel, Darren K. McGuire · 2019 · Nature Reviews Cardiology
  25. Diabetes Mellitus as an Integrated Microbiome, Immune, and Metabolic Disorder with Clinical Implications for Multisystem Complications and Public Health
    Ayman Elbehiry, Eman Marzouk, Fahad Abdulrahman Alhumaydhi, Adil Abalkhail · 2026 · Journal of Clinical Medicine
  26. Impact of Glycemic Control on Coronary Inflammation Evaluated by Computed Tomography Pericoronary Fat Attenuation Index in Patients with Acute Coronary Syndrome
    Jinyao Jiang, Yan Yin, Yilin Li, Bihe Xu, Zhiguo Zou, Song Z. Ding, Jun Pu · 2023 · Reviews in Cardiovascular Medicine
  27. Changes over time in the cardiovascular risk profile of type 2 diabetes from 2007 to 2020: A community‐based study
    Brent A. Williams, Jonathan P. Brady, Stephen J. Voyce, Neela Kumar, Yurek Paprocki, JIGAR R. RAJPURA · 2022 · Diabetes Obesity and Metabolism
  28. Differential Impact of Degree of Hypertension on Subclinical Coronary Atherosclerosis in Asymptomatic Subjects With and Without Diabetes Mellitus
    Hyun Woo Park, Sangyong Jo, Kyung Sun Park, Hyeji Lee, Young‐Jee Jeon, Sangwoo Park, Soe Hee Ann, Yong‐Giun Kim, Seong Hoon Choi, Woon Jung Kwon et al. · 2023 · The American Journal of Cardiology
  29. Medical management of risk factors for vascular disease
    Amy Rose Sharkey, Bijan Modarai · 2018 · Surgery (Oxford)
  30. Impact of Intensive Glucose Control in Patients with Diabetes Mellitus Undergoing Percutaneous Coronary Intervention: 3-Year Clinical Outcomes
    Jiesuck Park, Jung‐Kyu Han, Mineok Chang, You‐Jeong Ki, Jeehoon Kang, Han‐Mo Yang, Hyun‐Jai Cho, Kyung Woo Park, Hyun‐Jae Kang, Bon‐Kwon Koo et al. · 2020 · Journal of Clinical Medicine
  31. Safety, feasibility and efficacy of metformin and sitagliptin in patients with a TIA or minor ischaemic stroke and impaired glucose tolerance
    Elizabeth Osei, Adrienne A.M. Zandbergen, Paul J.A.M. Brouwers, Laus J.M.M. Mulder, Peter J. Koudstaal, Hester Floor Lingsma, Diederik W.J. Dippel, Heleen den Hertog · 2021 · BMJ Open
  32. Molecular Correlates of Early Onset of Diabetic Cardiomyopathy: Possible Therapeutic Targets
    Dongjuan Wang, Kun Liu, Jinyan Zhong, Xin Li, Jie Zhang, Gongxin Wang, Ni Li, Tianwen Li, Harvey Davis, Ibrahim El-gaby et al. · 2022 · Oxidative Medicine and Cellular Longevity
  33. Divergent impacts of glycemic control on mortality and complications in patients with early-versus late-onset type 2 diabetes: A retrospective cohort study
    Haipeng Ma, Jitao Zhang, Bing Meng, Kai Wang, Yuhong Li, Na Liang · 2025 · PLoS ONE
  34. The Correlation Between C-Peptide and Severity of Peripheral Atherosclerosis in Type 2 Diabetes Mellitus
    Maisa A. Abdel Wahab, Alshaymaa M. Alhabibi, Ahmed Khairy Sakr, Mohamed Yahia Zakaria, Ola I. Saleh, Inass Hassan Ahmad, Eman Abdelrahman, Randa Ibrahim Taha, Fayka Karem Abdel Azeem Ahmed, Bothayna Ismail et al. · 2023 · Diabetes Metabolic Syndrome and Obesity
  35. Effect of delay in treatment intensification in people with type 2 diabetes and suboptimal glycaemia after basal insulin initiation: A real‐world observational study
    Sharmin Shabnam, Sophia C. Abner, Clare L. Gillies, Melanie Jane Davies, TERRY A. DEX, Kamlesh K. Khunti, David R. Webb, Francesco Zaccardi, Samuel Seidu · 2023 · Diabetes Obesity and Metabolism
  36. Treatment of diabetes mellitus has borne much fruit in the prevention of cardiovascular disease
    Hiroaki Yagyu, Hitoshi Shimano · 2022 · Journal of Diabetes Investigation
  37. Clinical trials with reno-vascular end points in patients with diabetes: Changing the scenario over the past 20 years
    Tomasz J. Block, Mark Emmanuel Cooper · 2023 · La Presse Médicale
  38. ADDITION-Europe: the first decade and beyond
    Takayoshi Sasako, Takashi Kadowaki, Kohjiro Ueki · 2019 · The Lancet Diabetes & Endocrinology
  39. Role of Glucose and Lipids in the Atherosclerotic Cardiovascular Disease of Patients with Diabetes
    Kenneth R. Feingold · 2020 · Europe PMC (PubMed Central)
  40. Immune Dysregulation Connecting Type 2 Diabetes and Cardiovascular Complications
    Katherine S. Deck, Christoph J. Mora, Shuoqiu Deng, Pamela Rogers, Tonya M. Rafferty, Philip Palade, Shengyu Mu, Yunmeng Liu · 2025 · Life
  41. Supramolecular wearable patch for continuous non-invasive blood glucose monitoring
    Zhaoxiang Li, Minghao Zhao, Yueyue Chen · 2026 · Supramolecular Materials
  42. Add-on therapy with dapagliflozin in routine outpatient care of type 2 diabetes patients from Turkey: a retrospective cohort study on HbA1c, body weight, and blood pressure outcomes
    Derun Taner Ertuğrul, Erdal Kan, Çiğdem BAHADIR TURA, Haci Bayram Tugtekin, Hayati Ayakta, Mehmet ÇELEBİOĞLU, Ceren Yılmaz, Onur ÜTEBAY, İlhan Yetkin, The DAPATURK Study Group et al. · 2021 · International Journal of Diabetes in Developing Countries
  43. Multifactorial Intervention on Type 2 Diabetes ( MIDiab ) Study: A multicenter, open‐label , randomized, parallel controlled, community trial
    Yupeng Wang, Qingbo Guan, Xu Hong Hou, Xu Zhang, Haiqing Zhang, Chao Xu, Fei Jing, Shizhan Ma, Shanshan Shao, Meng Zhao et al. · 2020 · Journal of Diabetes
  44. Use of cardiovascular imaging in risk restratification of the diabetic patient
    Jamie W. Bellinge, Sing Ching Lee, Carl Johann Schultz · 2020 · Current Opinion in Endocrinology Diabetes and Obesity
  45. Lowering hemoglobin A1c level to less than 6.0% in people with type 2 diabetes may reduce major adverse cardiovascular events: a Bayesian’s narrative
    Hui Shao, Jingchuan Serena Guo, Neda Laiteerapong, Shichao Tang, Vivian Andrew Fonseca, Lizheng Shi, Ping Zhang · 2022 · Current Medical Research and Opinion
  46. The economic value of insulin glargine 300 U/mL (Gla-300) in people ≥18 years of age with type 2 diabetes mellitus: a value-based economic model from a U.S. payer perspective
    Ekaterina Ponomareva, Luke M. Schmerold, Srinivas SSS, Ronald Preblick, Seojin Park, Laura Wilson, Andrew Revel · 2023 · Journal of Medical Economics
  47. Metabolic Perspective on Atherosclerosis: Macrophage Reprogramming and Novel Therapeutic Targets
    Z Q Wang, Ying Zhang, Lihua Li, Zhongqun Wang · 2026 · Journal of the American Heart Association
  48. Update Typ-2-Diabetes
    Andreas Hamann · 2020 · Der Diabetologe
  49. Long-term follow up of older people on diabetes medications: observational study using linked health databases
    Katharine Ann Wallis, Susan J. Wells, Vanessa Selak, Katrina Poppe · 2020 · Australian Journal of Primary Health
  50. Prevention of Cardiovascular Disease in Patients with Chronic Kidney Disease
    Robin H. Lo, Richard J. Glassock · 2020 · Contemporary cardiology
  51. Intensive lipid-lowering therapy, time to think beyond low-density lipoprotein cholesterol
    Ahmed Abdalwahab, Ayman Al‐Atta, Azfar Zaman, Mohammad Alkhalil · 2021 · World Journal of Cardiology
  52. Insulin Treatment of Diabetes Mellitus-Tight vs. Conventional Control
    Nicholas Emanuele, Peter D. Reaven · 2023 · Contemporary cardiology
  53. Use of Peak Glucose Level and Peak Glycemic Gap in Mortality Risk Stratification in Critically Ill Patients with Sepsis and Prior Diabetes Mellitus of Different Body Mass Indexes
    Yi‐Hsuan Tsai, Kai-Yin Hung, Wen‐Feng Fang · 2023 · Nutrients
  54. The evolution of type 2 diabetes management: glycemic control and beyond with SGLT-2 inhibitors and GLP-1 receptor agonists
    Thomas C. Serowik, Kevin M. Pantalone · 2023 · Journal of Osteopathic Medicine
  55. Dysregulated inflammatory response to urogynecologic meshes in women with diabetes and its implications
    Rui Liang, Eric Shaker, Muyun Zhao, Gabrielle E. King, Pamela Moalli · 2024 · American Journal of Obstetrics and Gynecology
  56. The History of the Development of SGLT2 Inhibitors for the Treatment of Diabetes: From Biology to Chemistry
    Mukesh Nandave · 2024 · Springer eBooks
  57. Stroke prevention in patients with type 2 diabetes mellitus or prediabetes: recommendations of the Spanish Society of Neurology’s Stroke Study Group
    Blanca Fuentes, Sergio Amaro, M. Alonso de Leciñana, Juan Francisco Arenillas, Óscar Ayo Martín, Mar Castellanos, M. Freijo, García-Pastor, Meritxell Gomis, M. Gómez Choco et al. · 2021 · Neurología (English Edition)
  58. In poorly controlled type 2 diabetes, oral semaglutide was noninferior to liraglutide for reducing HbA1c
    Lorraine Lucille Lipscombe · 2019 · Annals of Internal Medicine
  59. Cardiovascular Effects of Hypoglycemic Agents in Diabetes Mellitus
    Anna Pietraszek · 2020 · Current Drug Safety
  60. Risk factors for hypoglycaemia in people with diabetes admitted to the Emergency Department of a Hospital in French Guiana
    Fabien Poret, Mathieu Nacher, Jean Marc Pujo, Jean‐Michel Cauvin, Magalie Demar, Mickaël Massicard, Nadia Sabbah · 2021 · Diabetic Medicine
  61. Benefits of intensified reductions in blood glucose and in blood pressure for patients with type 2 diabetes
    Nelson Wang, Sophia Zoungas, John Philip Chalmers · 2022 · La Presse Médicale
  62. Diabetic cardiomyopathy: an educational review
    Su-Lee Xiao, Emilia Bober, Xenophon Kassianides, Francesco Medici, Han Xiao · 2023 · British Journal of Cardiology
  63. Update Kardiologie 2020
    Michael Lehrke · 2020 · Der Diabetologe
  64. Tratamiento de la diabetes tipo 2 en el paciente anciano: la seguridad es una prioridad
    José Antonio Gimeno Orna, B. García García · 2019 · Revista Clínica Española
  65. Die diabetische Angiopathie
    Kilian Rittig · 2020 · Diabetes aktuell
  66. Does sugar control arrest complications in type 2 diabetes? Examining rigor in statistical and causal inference in clinical trials
    Akanksha Ojha, Harshada Vidwans, Milind Watve · 2022 · medRxiv
  67. Does Sugar Control Arrest Complications in Type 2 Diabetes? Examining the Rigour in Statistical Methods and Causal Inference in Clinical Trials.
    Akankasha Ojha, Harshada Vidwans, Milind Watve · 2023 · Qeios
  68. In patients ≥ 50 years with type 2 diabetes and CV disease or risk factors, dulaglutide reduced CV outcomes
    Lorraine Lucille Lipscombe · 2019 · Annals of Internal Medicine
  69. Cost-Effectiveness of the New 2018 American College of Physicians Glycemic Control Guidance Statements Among US Adults With Type 2 Diabetes
    Hui Shao, Michael Laxy, Edward W. Gregg, Ann L. Albright, Ping Zhang · 2020 · Value in Health
  70. Medical management of risk factors for vascular disease
    Michael Greshan Rasiah, Bijan Modarai · 2021 · Surgery (Oxford)
  71. Sex differences in the reciprocal relationship between glycemic control and depressive symptoms among older adults with diabetes: Using a nationwide population‐based sample
    Gyeonga Kang, Chang Won Won, Miji Kim, Ju Young Yoon · 2023 · Geriatrics and gerontology international/Geriatrics & gerontology international
  72. Optimizing medical management and risk factors
    Michael Greshan Rasiah, Bijan Modarai · 2024 · Surgery (Oxford)
  73. Empagliflozin-based quadruple oral therapy for type 2 diabetes: a prospective cohort study
    Fatemeh Moosaie, Shiva Abedinzadeh, Soghra Rabizadeh, Kimia Daneshvar, Mohammadamin Noorafrooz, Fatemeh Mojtahedi, Niloofar Deravi, Seyede Marzie Fatemi Abhari, Akam Ramezani, Alipasha Meysamie et al. · 2025 · Scientific Reports
  74. Development and Internal Validation of the Multiethnic Type 2 Diabetes Outcomes Model for the U.S. (DOMUS)
    Aaron N. Winn, Zachary Newman, Amber N. Deckard, Melissa I. Franco, Erin M. Staab, Monica E. Peek, Anirban Basu, Philip Clarke, Wen Wan, Elbert S. Huang et al. · 2025 · Diabetes Care
  75. Optimizing Type 2 Diabetes Management: The Efficacy and Safety of Gliclazide in Clinical Practice
    Viswanathan Mohan, Brij Mohan Makkar, Banshi Saboo, Arvinda Jagadisha, Manoj S Chawla, Neeta Deshpande, Vipan Kumar Goyal, Rohit Kapoor · 2025 · Journal of Diabetology
  76. Glycated hemoglobin and cardiovascular risk in diabetes mellitus: Evolving evidence beyond glycemic control
    Manjeet Kumar Goyal, Juniali Hatwal, Rupak Desai, Tanisha Sehgal, Akash Batta · 2026 · World Journal of Diabetes
  77. A comparison of sotagliflozin therapy for diabetes mellitus between week 24 with week 52
    Nie Zhang, Zhiqun Gu, Yunlong Ding, Liu Yang, Mao-bing Chen, Qi-han Zheng · 2019 · Medicine
  78. Study of pulsed electrostatic field (PESF) in the perfusion of peripheral tissues: Microangiopathy, nutrition and quality of perceiver life
    Rossella Liani, Sara La Torre, Valentina Liani, Angela Melchiorre, Danilo D’Ettorre, Romina Tripaldi, Stefano Lattanzio, Rossano Di Luzio, Mauro Coli, Carlo Velussi · 2022 · PLoS ONE
  79. Recent Trials on the Cardioprotective Effects of New Generation Anti-diabetic and Lipid-Lowering Agents
    Omar Abdelfattah, Ahmed Sayed, Anas Al-Refaei, Jasmin Abdeldayem, Khaled Moustafa, Nicholas Elias, Yehia Saleh · 2023 · Frontiers in clinical drug research. Diabetes and obesity
  80. ADMIRE Study: Dapagliflozin and Metformin Fixed-dose Combination as Initial Choice of Therapy in Type 2 Diabetes Mellitus: A Real-world Study
    Uday Phadke, Jayashree Gopal, Kaushik Biswas, Priyanka Joshi, Ashish Prasad, Ashish Birla · 2024 · Chronicle of Diabetes Research and Practice
  81. Individual, interpersonal, and community factors associated with health outcomes in patients with type 2 diabetes mellitus treated at federally qualified health centers
    Asma M. Ali, Ewan Kemar Cobran, Henry Nolan Young · 2024 · Journal of Diabetes & Metabolic Disorders
  82. Prävention des ischämischen Schlaganfalls im Alter
    Bernhard Iglseder, Johannes Sebastian Mutzenbach · 2024 · Zeitschrift für Gerontologie und Geriatrie
  83. Two for the heart: Dutch Pharmacogenetic Working Group prescribing guidance on statins and sulfonylureas to reduce cardiometabolic risk
    Sean P. David · 2025 · European Journal of Human Genetics
  84. Altered leptin signaling and attenuated cardiac vagal activity in rats with type 2 diabetes
    Anthony J. Evans, Huiyin Tu, Yu Li, Boris Shabaltiy, Lauren Whitney, Kassidy Carpenter, Yu-long Li · 2025 · Frontiers in Physiology
  85. Methodological Tools for Exploring Novel Biopharmaceutical Approaches to the Metabolic Syndrome and Related Disorders
    Amedeo Lonardo, Enrica Baldelli · 2020 · Diabetes Therapy
  86. Maintenance of plasma glucose variability after an acute session of aerobic exercise despite changes in insulin and glucagon-like peptide-1 levels in type 2 diabetes
    Patrícia Martins Bock, Raíssa Borges Monteiro, Gabriela Berlanda, Karina Rabello Casali, Beatriz D'Agord Schaan · 2022 · Archives of Endocrinology and Metabolism
  87. Relationship of Glycemic Control with Level of Blood Pressure amongst Type 2 Diabetic Patients
    Saeed Ammarah, Zunera Jahanzeb, Uzma Batool, Samia Kauser, Mushtaq Muhammad, Nasir Mahmood · 2022 · Pakistan Journal of Medical and Health Sciences
  88. Atherosclerotic Cardiovascular Disease Prevention in the Older Adult: Part 2
    Ella Murphy, Marie Therese Cooney, John William McEvoy · 2023 · Contemporary cardiology
  89. Is clinical trial data showing positive progress for the treatment of diabetic kidney disease?
    Seng Kiong Tan, Mark Emmanuel Cooper · 2023 · Expert Opinion on Emerging Drugs
  90. In patients ≥ 50 years with type 2 diabetes and CV disease or risk factors, oral semaglutide did not increase CV events
    Lorraine Lucille Lipscombe · 2019 · Annals of Internal Medicine
  91. Treatment for type 2 diabetes in elderly patients: safety is a priority
    José Antonio Gimeno Orna, B. García García · 2019 · Revista Clínica Española (English Edition)
  92. Intensive Glukosekontrolle bei Patienten mit Diabetes Typ 2 – Ergebnisse nach 15 Jahren
    Johann Steurer · 2019 · Praxis
  93. Intensive Zuckersenkung wirkt nicht nach
    Emanuel Fritschka · 2019 · MMW - Fortschritte der Medizin
  94. Paradigm Shift for the Treatment of Type 2 Diabetes Mellitus in Patients with Cardiovascular Disease: Cardiologist's Perspective
    Doo Soo Jeon · 2020 · Cardiovascular Prevention and Pharmacotherapy
  95. Do You Have Any Risk Factors or Long-Term Health Conditions? How Environment, Lifestyle and Other Medical Conditions Are Linked to Kidney Disease
    H. Rayner, Mark E. Thomas, D. Milford · 2020 · Springer eBooks
  96. Primärprävention des Schlaganfalls
    Christian P Gerloff, Hans‐Christoph Diener · 2020 · Nervenheilkunde
  97. Prevalence and Risk Factors of Coronary Heart Disease in Chinese Patients with type 2 Diabetes Mellitus, 2013-2018
    Chenchen Wang, Zuoling Xie, Xi Huang, Zheng Wang, Haiyan Shangguan, Shaohua Wang · 2020
  98. Der kardiovaskulär vorerkrankte Diabetespatient
    Florian Kahles, Michael Lehrke · 2021 · MMW - Fortschritte der Medizin
  99. Gériatrie
    Grégoire Mary-Heck, Sonia Lajoso, Romain Schneider, Pauline Putallaz, Camille Cochet, Maria-angela Gagliano, Sarah Besse, Alexandre Da Silva Costa, Valeria Musumeci, Sylvain Nguyen et al. · 2020 · JMIG
  100. Control of Blood Glucose and Cardiovascular Risk Profile
    Stefano Ciardullo, Gianluca Perseghin · 2023 · Updates in hypertension and cardiovascular protection